Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study.

Background: Glanzmann thrombasthenia (GT) is caused by an inherited defect of platelet αβ integrin. Concizumab, a monoclonal antibody specific for tissue factor pathway inhibitor, abolishes its anticoagulant effect.

Objectives: To evaluate the in vitro ability of concizumab to improve hemostasis in GT.